Non Small Cell Lung Cancer Clinical Trial
Official title:
A Phase 1b Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) as 1st-line Treatment in Subjects With Non-Squamous Non-Small Cell Lung Cancer
Verified date | September 2020 |
Source | Mereo BioPharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to test the safety and determine the optimal dose of a new drug,
demcizumab (OMP-21M18), when given in combination with carboplatin and pemetrexed, a standard
drug treatment regimen for non-squamous non-small cell lung cancer (NSCLC). Participants must
not have received prior chemotherapy for their NSCLC. Demcizumab is a humanized monoclonal
antibody (a protein made in the laboratory) developed to target cancer stem cells. The way
the body handles demcizumab will also be investigated.
Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain.
Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your
eligibility to take part in this study, and then if enrolled in the study you will receive
intravenous (in the vein) infusions of the demcizumab, carboplatin, and pemetrexed
administered on the same day, every 21 days for 4 cycles, or until it has been shown that
your cancer has progressed. If your physician decides to delay treatment with one of the
agents due to side effects, the other agents may still be administered as scheduled. After 4
cycles, if you have stable or improved disease, you will continue to receive pemetrexed once
every 21 days as maintenance therapy. You will undergo assessments every 8 weeks to determine
the status of your disease.
Status | Completed |
Enrollment | 50 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion criteria 1. Subjects must have histologically confirmed unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC. Subjects may not have received prior therapy for their unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC. Subjects may have received prior surgery, prior radiotherapy, and/or prior neoadjuvant or adjuvant chemotherapy (they must have discontinued prior neoadjuvant or adjuvant chemotherapy at least 12 weeks prior to study entry). 2. Age >21 years 3. ECOG performance status <2 (see Appendix B) 4. Life expectancy of more than 3 months 5. Subjects must have normal organ and marrow function as defined below: - Leukocytes >3.5 x 109/L - Absolute neutrophil count >1.25 x 109/L Hemoglobin >100 g/L - Platelets >125 X 109/L - Total bilirubin <2 X institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) <5 X institutional ULN - Alkaline phosphatase <5 X institutional ULN - International normalized ratio (INR) and activated partial thromboplastin time (aPTT) within institutional ULN - Calculated creatinine clearance >60 mL/min using the Cockcroft and Gault formula as follows: Creatinine clearance (mL/min) = (140 - age) x ideal body weight [kg] 0.814 x serum creatinine [µmol/L] For women multiply the value from the equation above by 0.85. Where age is in years, weight is in kg, and serum creatinine is in µmol/L. 6. Women of childbearing potential must have had a prior hysterectomy or have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drugs. Men must also agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and from study entry through at least 6 months after discontinuation of study drugs. Should a woman enrolled in the study or a female partner of a man enrolled in the study become pregnant or suspect she is pregnant while participating in this study or within 6 months after discontinuation of the study drugs, the Investigator should be informed immediately. 7. Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria Subjects who meet any of the following criteria will not be eligible for participation in the study: 1. Subjects receiving any other investigational agents or anti-cancer therapy. 2. Subjects with brain metastases (subjects must have a CT scan or MRI of the head within 28 days prior to enrollment to rule out brain metastases), uncontrolled seizure disorder, or active neurologic disease 3. History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy 4. Significant intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements 5. Pregnant women or nursing women 6. Subjects with known HIV infection 7. Known bleeding disorder or coagulopathy 8. Subjects receiving heparin, warfarin, or other similar anticoagulants. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents. 9. Subjects with known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease 10. New York Heart Association Classification II, III, or IV (See Appendix D) 11. Subjects with a blood pressure of >140/90 mmHg. The BP should be taken using the method described in Section 9.3. Subjects taking antihypertensive medications must be taking = 2 medications to obtain this level of BP control. 12. Subjects with metastases that are currently involving the lumen of the gastrointestinal tract 13. Subjects with squamous cell carcinoma of the lung 14. Subjects with recent (within the last 8 weeks) hemoptysis >2.5 mL and subjects with serious bleeding from another site within this timeframe 15. Subjects with current evidence of cardiac ischemia or heart failure within the last 6 months, subjects who are receiving any medications for cardiac ischemia, subjects with a B-type natriuretic peptide (BNP) value of >100 pg/mL, subjects with a LVEF <50%, subjects with pulmonary hypertension defined as a peak tricuspid velocity >3.4 m/s on doppler echocardiogram or subjects that have received a total cumulative dose of =400 mg/m2 doxorubicin. 16. Subjects with ECG evidence of ischemia or = Grade 2 ventricular arrhythmia, subjects who have a history of acute myocardial infarction within 6 months, or subjects with unstable angina. |
Country | Name | City | State |
---|---|---|---|
Australia | Monash Medical Centre | Clayton | Victoria |
Australia | Royal Brisbane & Women's Hospital | Herston | Queensland |
Australia | Ashford Cancer Centre Research | Kurralta Park | South Australia |
Australia | Sir Charles Gairdner Hospital | Nedlands | Western Australia |
New Zealand | Auckland Hospital | Grafton | Auckland |
New Zealand | Waikato Hospital | Hamilton | |
Spain | START Madrid | Madrid |
Lead Sponsor | Collaborator |
---|---|
OncoMed Pharmaceuticals, Inc. | Novotech (Australia) Pty Limited |
Australia, New Zealand, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To the determine the maximum tolerated dose of demcizumab (OMP-21M18) plus carboplatin and pemetrexed | When each patient in the dose cohort reaches Day 56 | ||
Secondary | To determine the safety of carboplatin and pemetrexed plus demcizumab (OMP-21M18) | until treatment termination plus 30 days | ||
Secondary | To determine the rates of immunogenicity of carboplatin and pemetrexed plus demcizumab (OMP-21M18) | Up to 12 weeks post treatment termination | ||
Secondary | To determine the preliminary efficacy of carboplatin and pemetrexed plus demcizumab (OMP-21M18) | Until disease progression | ||
Secondary | To determine population pharmacokinetics | Day 21 and 63 | ||
Secondary | To determine the exploratory biomarker changes of carboplatin and pemetrexed plus demcizumab (OMP-21M18) | Until Day 112 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |